AGY Stock Overview
A commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Allergy Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.065 |
| 52 Week High | UK£0.08 |
| 52 Week Low | UK£0.027 |
| Beta | 1.23 |
| 1 Month Change | 0% |
| 3 Month Change | -9.72% |
| 1 Year Change | 128.07% |
| 3 Year Change | -72.04% |
| 5 Year Change | -49.02% |
| Change since IPO | -91.28% |
Recent News & Updates
Recent updates
Allergy Therapeutics plc (LON:AGY) Soars 27% But It's A Story Of Risk Vs Reward
Nov 09
Not Many Are Piling Into Allergy Therapeutics plc (LON:AGY) Just Yet
Sep 12Allergy Therapeutics plc's (LON:AGY) 28% Share Price Surge Not Quite Adding Up
May 21Allergy Therapeutics plc (LON:AGY) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Dec 18Shareholder Returns
| AGY | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 12.1% | 2.9% | 1.6% |
| 1Y | 128.1% | -10.7% | 1.5% |
Return vs Industry: AGY exceeded the UK Pharmaceuticals industry which returned -7.7% over the past year.
Return vs Market: AGY exceeded the UK Market which returned 2% over the past year.
Price Volatility
| AGY volatility | |
|---|---|
| AGY Average Weekly Movement | 12.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: AGY's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: AGY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 612 | Manuel Llobet | www.allergytherapeutics.com |
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus.
Allergy Therapeutics plc Fundamentals Summary
| AGY fundamental statistics | |
|---|---|
| Market cap | UK£307.44m |
| Earnings (TTM) | -UK£35.65m |
| Revenue (TTM) | UK£55.66m |
5.6x
P/S Ratio-8.7x
P/E RatioIs AGY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGY income statement (TTM) | |
|---|---|
| Revenue | UK£55.66m |
| Cost of Revenue | UK£25.58m |
| Gross Profit | UK£30.08m |
| Other Expenses | UK£65.73m |
| Earnings | -UK£35.65m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0075 |
| Gross Margin | 54.04% |
| Net Profit Margin | -64.05% |
| Debt/Equity Ratio | -523.9% |
How did AGY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/24 02:32 |
| End of Day Share Price | 2025/04/24 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Allergy Therapeutics plc is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam McCarter | Cavendish |
| Gary Waanders | Nomura Code Securities Limited |
| Paul Cuddon | Numis Securities Ltd. |